Safety and performance of a resorbable magnesium scaffold under real-world conditions: 12-month outcomes of the first 400 patients enrolled in the BIOSOLVE-IV registry
EuroIntervention 2019; just accepted article published in January 2019. DOI: 10.4244/EIJ-D-18-01058
Stefan Verheye1; Adrian Wlodarczak2; Piero Montorsi3; Johan Bennett4; Jan Torzewski5; Michael Haude6; Mathias Vrolix7; Thomas Buck8; Adel Aminian9; Rene J van der Schaaf10; Amin Arrif Nuruddin11; Michael K Y Lee12;
1. Interventional Cardiology, ZNA Cardiovascular Center Middelheim, Antwerp, Belgium, BELGIUM; 2. Miedziowe Centrum Zdrowia S.A., Lublin, Poland; 3. Department of Clinical Sciences and Community Health, University of Milan and Centro Cardiologico Monzino, IRCCS, Milan, Italy; 4. Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; 5. Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany; 6. Medical Clinic I Städtische Kliniken Neuss Lukaskrankenhaus GmbH, Neuss, Germany; 7. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; 8. Department of Cardiology, Klinikum Westfalen, Knappschaft KH, Dortmund, Germany; 9. Centre Hospitalier Universitaire de Charleroi, Department of Cardiology, Charleroi, Belgium; 10. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; 11. Institute Jantung Negara, Kuala Lumpur, Malaysia; 12. Division of Cardiology, Queen Elizabeth Hospital, Kowloon, Hong Kong
Disclaimer:
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention -
has been published immediately upon acceptance as it was received. The content of this article is the sole
responsibility of the authors, and not that of the journal or its publishers.
To read the full content of this article, please log in to download the PDF.
Aims: We aimed to assess the safety and performance of the Magmaris bioresorbable magnesium scaffold in a large patient population.
Methods and results: BIOSOLVE-IV is an international, single arm, multi-center registry. This is the pre-defined report on 12-month outcomes of the first 400 out of 2054 patients planned. Mean patient age was 62.0±11.0 years and 15.8% (n=63) had non-ST-elevation myocardial infarction. Lesions (n=425) were 3.3±0.3 mm in diameter and 14.5±4.1 mm long. The primary endpoint, target lesion failure at 12 months, occurred in 4.3% [95%CI:2.7;6.9], consisting of 4.3% target lesion revascularizations, 0% cardiac death, and 0.8% target-vessel myocardial infarction. One definite scaffold thrombosis occurred on post-procedure day 10 after cessation of dual antiplatelet therapy.
Conclusions: The preliminary analysis of the first 400 patients enrolled in BIOSOLVE-IV confirms the safety and performance of the Magmaris scaffold in clinical routine.
